Fig. 2.

Drug release from novel core-matrix MZC and MZCL IVRs in vivo. This figure details the PK profile of the MZCL vs. MZC IVRs overall (a, b) and per particular IVR design (c, d, e). (a) At the indicated times post-insertion (PI) and post-removal (PR) in macaques carrying MZCL or MZC IVRs, MIV-150 was measured in blood and vaginal fluid (VF), and CG was measured in vaginal fluid. (b) LNG was similarly measured in the blood of macaques carrying MZCL or LNG IVRs. To show the overall difference between MZCL and MZC IVRs, in (a) and (b), data were pooled from macaques carrying IVRs of different pore sizes and from IVR cycles 1 and 5. Thus, mean ± SEM is shown for 24 MZCL IVRs (12 from IVR-1 and 12 from IVR-5), 24 MZC IVRs (12 from IVR-1 and 12 from IVR-5), and 8 LNG IVRs (4 from IVR-1 and 4 from IVR-5). The breakdown by pore size and IVR cycle (n = 6 each) is shown for (c) MIV-150 and CG and (d) LNG. (e) The total amounts of MIV-150, CG, and LNG detected in vivo were determined by analyzing area under the curve (AUC) of the data in (c) and (d). For MIV-150 and LNG, closed symbols represent 500 μm pore IVRs and open symbols represent 800 μm pore IVRs. For CG, closed symbols represent IVR-1 and open symbols represent IVR-5